Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors.

Abstract

Novel treatment options are needed for testicular germ cell tumor (TGCT) patients, particularly important for those showing or developing cisplatin resistance, the major cause of cancer-related deaths. As TGCTs pathobiology is highly related to epigenetic (de)regulation, epidrugs are potentially effective therapies. Hence, we sought to explore, for the first time, the effect of the two most recently FDA-approved HDAC inhibitors (HDACis), belinostat and panobinostat, in (T)GCT cell lines including those resistant to cisplatin. In silico results were validated in 261 patient samples and differential expression of HDACs was also observed across cell lines. Belinostat and panobinostat reduced cell viability in both cisplatin-sensitive cells (NCCIT-P, 2102Ep-P, and NT2-P) and, importantly, also in matched cisplatin-resistant subclones (NCCIT-R, 2102Ep-R, and NT2-R), with IC50s in the low nanomolar range for all cell lines. Treatment of NCCIT-R with both drugs increased acetylation, induced cell cycle arrest, reduced proliferation, decreased Ki67 index, and increased p21, while increasing cell death by apoptosis, with upregulation of cleaved caspase 3. These findings support the effectiveness of HDACis for treating TGCT patients in general, including those developing cisplatin resistance. Future studies should explore them as single or combination agents.

• Authors: João Lobo, Catarina Guimarães-Teixeira, Daniela Barros-Silva, Vera Miranda-Gonçalves, Vânia Camilo, Rita Guimarães, Mariana Cantante, Isaac Braga, Joaquina Maurício, Christoph Oing, Friedemann Honecker, Daniel Nettersheim, Leendert Hj Looijenga, Rui Henrique, Carmen Jerónimo
• Journal: Cancers (Cancers (Basel)) Vol. 12 Issue 10 (Oct 10 2020) ISSN: 2072-6694 [Print] Switzerland
• PMID: 33050470 (Publication Type: Journal Article)